Authors : Dr. N. Junior Sundresh; Gopiha Shri G. S.; Vinisha P. S.

Volume/Issue : Volume 10 - 2025, Issue 9 - September

Google Scholar : https://tinyurl.com/46st6the

Scribd : https://tinyurl.com/3vy94run

DOI : https://doi.org/10.38124/ijisrt/25sep360

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Background: Postoperative pancreatic complications such as pancreatic fistula, hyperamylasemia, and stress-related mucosal injury are significant concerns following pancreatic surgeries. Pharmacological agents like octreotide and omeprazole have been suggested to play a preventative role by inhibiting pancreatic secretion and gastric acid production, respectively.  Objective: The goal of this study was to check how well octreotide and omeprazole, either alone or together, work in preventing problems in the pancreas after surgery in patients who had planned surgery on their pancreas.  Methods: A study was done on 60 patients who were having planned surgery on their pancreas. The patients were split into three groups: one group got octreotide only, another got omeprazole only, and the third group got both medicines together. We kept track of several things that happened after the surgery, like how often complications such as pancreatic fistula, high amylase levels, stress ulcers, and the length of hospital stay occurred. Blood tests were done at 24, 48, 72 hours after the surgery to check levels of amylase in the blood.  Results: The group that received both medicines together had much fewer cases of pancreatic fistula and high amylase levels compared to the groups that received only one medicine. Octreotide and omeprazole individually showed modest effectiveness, but when used together, they significantly reduced postoperative enzyme levels and complication rates (p < 0.05). No significant adverse effects were noted in any group.  Conclusion: The combination of octreotide and omeprazole offers a synergistic effect in minimizing postoperative pancreatic complications. Integration of both agents into perioperative care protocols can improve surgical outcomes and reduce patient morbidity following pancreatic procedures.

Keywords : Octreotide, Omeprazole, Pancreatic Surgery, Pancreatic Fistula, Hyperamylasemia, Postoperative Complications, Stress-Related Mucosal Injury, Prophylaxis, Combination Therapy, Hospital Stay.

References :

1. Yeo CJ, Cameron JL. Prognostic factors in pancreatic cancer. Ann Surg. 1995;221(3):291–300.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–15.
3. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.
4. Kawai M, Tani M, Hirono S, et al. Risk factors for clinically relevant pancreatic fistula after pancreaticoduodenectomy. World J Surg. 2010;34(1):121–128.
5. Shrikhande SV, Barreto SG, Sivasanker M, et al. Evolution of pancreatojejunostomy after pancreaticoduodenectomy. J Am Coll Surg. 2012;214(5): e25–33.
6. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM Jr. Clinical and economic validation of the International Study Group of Pancreatic Fistula classification. Ann Surg. 2007;245(3):443–451.
7. Loos M, Strobel O, Legominski M, et al. Hyperamylasemia after pancreatic surgery. Ann Surg. 2016;264(5):877–884.
8. Ecker BL, McMillan MT, Asbun HJ, et al. Characterization and risk factors for postoperative pancreatic fistula after distal pancreatectomy. JAMA Surg. 2016;151(9):843–849.
9. Nikfarjam M, Wilson JS, Smith RC, et al. A model of postoperative pancreatic fistula following distal pancreatectomy. ANZ J Surg. 2011;81(10):718–723.
10. Martin RC, Brown R, Puffer L, McMasters KM. Prevention of pancreatic fistulas after pancreaticoduodenectomy. Am J Surg. 2004;188(1):1–6.
11. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31(11):1133–1140.
12. Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl. 1986; 119:54–64.
13. Gouillat C, Gigot JF. Pancreatic surgical complications—the case for prophylaxis. Gut. 2001;49(Suppl 5): v32–v39.
14. Suc B, Msika S, Piccinini M, et al. Octreotide in the prevention of complications following pancreatic surgery. Arch Surg. 2004;139(3):288–294.
15. Lowy AM, Lee JE, Pisters PW, et al. Octreotide to prevent pancreatic fistula after pancreaticoduodenectomy. Ann Surg. 1997;226(5):632–641.
16. Kurumboor P, Palaniswami KN, Pramil K, et al. Octreotide does not prevent fistula in soft pancreas patients. J Gastrointest Surg. 2015;19(11):2038–2044.
17. Bhatia N, Saraya A, Khosla SN. Omeprazole: a novel proton pump inhibitor. Indian J Gastroenterol. 1995;14(2):65–68.
18. Tewari M, Kumar V, Shukla HS. Role of omeprazole in surgical stress ulcer prophylaxis. Trop Gastroenterol. 2004;25(3):120–122.
19. Krasa HB. Acid suppression and pancreatic stimulation. Dig Dis Sci. 2003;48(7):1194–1198.
20. McClave SA, Martindale RG, Vanek VW, et al. Guidelines for nutritional support in critically ill patients. JPEN J Parenter Enteral Nutr. 2009;33(3):277–316.
21. Chen Z, Fu H, Fang J, et al. Preventive value of octreotide plus PPI on post-ERCP pancreatitis. Exp Ther Med. 2021;21(3):251.
22. Liu H, Chen X, Han Y. Comparison of octreotide and proton pump inhibitor in preventing acute pancreatitis after ERCP. Signa Vitae. 2023;19(5):238–243.
23. Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2007;102(1):46–51.
24. Wang J, Shen Y, Zhong Z, et al. Role of octreotide and NSAIDs in preventing post-ERCP pancreatitis. Med Sci Monit. 2018; 24:8964–8969.
25. Zhang Y, Chen QB, Gao ZY, et al. Meta-analysis: octreotide prevents post-ERCP pancreatitis. Aliment Pharmacol Ther. 2009;29(11):1155–1164.
26. Zhou X, Long J, Wang H, et al. Clinical observation of octreotide and diclofenac sodium for ERCP-related pancreatitis. Am J Transl Res. 2021;13(7):7179–7185.
27. Kim JS, Lee SH, Park N, et al. Nafamostat mesilate for post-ERCP pancreatitis. BMC Gastroenterol. 2022; 22:271.
28. Sperna Weiland CJ, Smeets XJNM, et al. Non-steroidal anti-inflammatory drugs and PEP prevention. Lancet Gastroenterol Hepatol. 2021;6(5):350–358.
29. Cahyadi O, Tehami N, de-Madaria E, et al. Post-ERCP pancreatitis: prevention and management. Medicina. 2022;58(9):1261.
30. Akshintala VS, Husain SZ, Brenner TA, et al. INTRO Trial: Rectal NSAIDs, tacrolimus for post-ERCP pancreatitis. Pancreatology. 2022;22(6):